Core Viewpoint - Shanghai is promoting the orderly opening and application of clinical data to enhance the development of the high-end medical device industry, which is considered one of the three leading industries in the city [1][7]. Group 1: Action Plan Overview - On September 15, Shanghai released a three-year action plan aimed at promoting the full-chain development of the high-end medical device industry, with goals set for 2027 [2]. - The action plan targets the approval of over 500 new domestic Class III medical device registrations and over 100 medical device products approved in overseas markets [2]. - The plan aims to cultivate two leading enterprises with an annual output value exceeding 10 billion and establish three high-end medical device industry clusters [2]. Group 2: Industry Development and Focus Areas - The medical device industry in Shanghai has rapidly developed, with a manufacturing output value of 55.51 billion, accounting for 27.6% of the biopharmaceutical output [3]. - The action plan outlines seven areas of focus, deploying 20 key tasks related to innovation, clinical empowerment, review and approval, hospital application, enterprise cultivation, industrial ecology, and international development [3]. Group 3: Key Product Development - The action plan emphasizes the development of "7+X" key products, including high-end medical imaging products, high-end implantable products, high-end surgical systems, high-end in vitro diagnostic products, high-end radiation therapy products, high-end rehabilitation products, high-end artificial intelligence medical devices, and future innovative devices [6]. - Shanghai aims to enhance its innovation capabilities by tackling cutting-edge technologies such as brain-computer interfaces and integrated diagnosis and treatment [6]. Group 4: Regulatory and Financial Support - The action plan proposes to strengthen pre-guidance services for the registration review of Class II and III innovative medical devices, aiming to reduce the average review time for Class II devices to within 40 working days [8][9]. - Financial support will be provided through collaboration between leading industry funds and biopharmaceutical merger funds, focusing on disruptive and cutting-edge technology innovations [10]. - Shanghai Guotou will prioritize investments in key areas such as brain-computer interfaces and high-end medical equipment, providing capital support for core technology development and process optimization [10].

8月25日，透景生命盘中上涨9.28%，截至13:29，报28.38元/股，成交5.25亿元，换手率14.3%，总市值 46.13亿元。 资料显示，上海透景生命科技股份有限公司位于上海市浦东新区汇庆路412号，公司主要从事高端体外 诊断产品的研发、生产、推广和销售，以流式荧光技术、化学发光技术、多重荧光PCR技术和液相色谱 串联质谱技术为主要技术平台，主要应用方向包括肿瘤全程监测、自身免疫、心血管疾病、病原体感染 及生殖健康等。至今，公司已累计获得近300项医疗器械注册证，并于2017年成功上市，股票代码为 300642。 截至3月31日，透景生命股东户数1.7万，人均流通股8081股。 2025年1月-3月，透景生命实现营业收入7489.31万元，同比减少19.53%；归属净利润47.17万元，同比增 长110.51%。 ...